<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805632</url>
  </required_header>
  <id_info>
    <org_study_id>Sputnik_HD</org_study_id>
    <nct_id>NCT04805632</nct_id>
  </id_info>
  <brief_title>Immune Response in Dialysis Patients Vaccinated Against SARS-CoV-2</brief_title>
  <acronym>Sputnik-HD</acronym>
  <official_title>A Comparison of Short-term and Mid-term Immune Response in Dialysis Patients and Staff Vaccinated Against SARS-CoV-2 Using Gam-COVID-Vac (Sputnik V) Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study aimed to evaluate short- and mid-term immune response&#xD;
      after SARS-CoV-2 vaccination using Gam-COVID-Vac (Sputnik V) vaccine in dialysis patients&#xD;
      compared to the control group (medical staff).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and aims: Patients receiving kidney replacement therapy with dialysis are at high&#xD;
      risk of infection and death from COVID-19. There is a lack of evidence whether SARS-CoV-2&#xD;
      vaccination is effective in this immunocompromised group.&#xD;
&#xD;
      Study design: this is a prospective cohort study. Two cohorts will be included: dialysis&#xD;
      patients and controls (medical staff), both vaccinated with Gam-COVID-Vac (Sputnik V)&#xD;
      vaccine.&#xD;
&#xD;
      Blood samples will be collected at 28 days and 22 weeks after after the second SARS-CoV-2&#xD;
      vaccine dose administration.&#xD;
&#xD;
      The primary outcome is the level of SARS-CoV-2 IgG antibodies on day 28 after the second&#xD;
      vaccination as compared to controls.&#xD;
&#xD;
      The secondary outcomes are: 1) the level of SARS-CoV-2 IgG antibodies on week 22 after the&#xD;
      second vaccination; 2) T cell subtype immunity measured by SARS-CoV-2 interferon-γ release&#xD;
      assays (IGRA) 28 days and 22 weeks after the second vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral response to vaccination against against SARS-CoV-2 as compared to controls</measure>
    <time_frame>28 days after the second vaccination</time_frame>
    <description>SARS-CoV2 IgG levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral response to vaccination against against SARS-CoV-2</measure>
    <time_frame>22 weeks after the second vaccination</time_frame>
    <description>SARS-CoV2 IgG levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell response against SARS-CoV-2</measure>
    <time_frame>28 days after the second vaccination</time_frame>
    <description>SARS-CoV-2 specific T-cell subtype measured by interferon-γ release assays (IGRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell response against SARS-CoV-2</measure>
    <time_frame>22 weeks after the second vaccination</time_frame>
    <description>SARS-CoV-2 specific T-cell subtype measured by interferon-γ release assays (IGRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 incidence</measure>
    <time_frame>22 weeks after the second vaccination</time_frame>
    <description>Survey of the incidence of SARS-CoV-2 infections over the study period</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Covid19</condition>
  <condition>Chronic Kidney Disease 5D</condition>
  <arm_group>
    <arm_group_label>Dialysis</arm_group_label>
    <description>Patients on hemodialysis or peritoneal dialysis who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Medical staff who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects ≥ 18 years old who were vaccinated twice against SARS-CoV-2 using Gam-COVID-Vac&#xD;
        (Sputnik V) vaccine.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 years or older&#xD;
&#xD;
          -  Previously vaccinated against SARS-CoV-2 with two administrations of Gam-COVID-Vac&#xD;
             (Sputnik V) vaccine&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of previous COVID-19 disease&#xD;
&#xD;
          -  Active malignancy of any localization&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Maintenance treatment with immunosuppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint-Petersburg State University Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Parshina, MD</last_name>
      <phone>+7(812)676-25-21</phone>
      <email>pannn@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Ekaterina Parshina</investigator_full_name>
    <investigator_title>Principal investigator, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

